News

The NObreath® FeNO device offers a clear pathway to more effective asthma care, reducing over-reliance on blue inhalers. Bedfont® Scientific Limited, an innovative med-tech company specialising in medical breath analysis devices, welcomes the new study at University Hospital Southampton exploring...

Bedfont® Scientific Limited believes balanced teams drive better decision-making, stronger innovation, and long-term success. Bedfont® Scientific Limited, a well-established Med-Tech company with over 49 years of expertise in the design and manufacture of medical breath analysis devices, is celebrating the...

Bedfont® ensures exercise books reach UK classrooms through sponsorship. Bedfont® Scientific Limited, a world leader in breath analysis, with nearly 50 years of expertise in the medical device industry, has teamed up with Rymindr, a social-tech company, to deliver vital...

Asthma is a chronic lung condition that causes airway inflammation and affects approximately 262 million people worldwide1. Typical symptoms include: Wheezing, Breathlessness, Chest tightness, Coughing. When airways are inflamed, breathing can become difficult. Recent Asthma + Lung UK research found...

Intermedical UK proudly delivers the 3,000th NObreath® FeNO device to the UK market. Bedfont® Scientific Limited, a medical device manufacturer based in Kent, with over 49 years’ experience in the breath analysis industry, was pleased to support its UK distributor,...

Innovative NObreath® FeNO device is the allergists' device of choice in the USA. coVita™ LLC, a leader in advanced breath analysis and diagnostic solutions, serves as the U.S. distributor for the innovative NObreath® Fractional Exhaled Nitric Oxide (FeNO) device from...